Pancreatic Neuroendocrine Tumors
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible cases for registration must meet all of the following criteria 1. Preoperative contrast-enhanced CT and EUS examinations were performed, followed by definitive surgical resection between January 1996 and December 2024, with a final pathological diagnosis of pancreatic neuroendocrine tumor (including NEC G3 and MiNEN) based on the resected specimen. Surgical techniques are not restricted. 2. Ki-67 imuunostaining was performed on the resected specimen and the Ki-67 labeling index is available. 3. Malignancy grading (NET G1, G2, G3, NEC) based on the WHO 2019 classification is feasible using the resected specimen.
Exclusion criteria
Exclusion criteria: Cases meeting the following criteria will be excluded: 1. Surgical resection of recurrence lesions only (e.g., liver metastases, lymph nodes). 2. Surgical resection of metastatic lesions solely for the purpose of mass reduction or alleviation of hormone-producing symptoms. 3. Cases that are difficult to differentiate from conventional pancreatic cancer in pathological diagnosis. 4. MiNEN. 5. Cases deemed unsuitable for this study by the principal investigator or co-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concordance rate between the prediction model and the Grade of resected specimens. | — |
Countries
Japan
Contacts
Public ContactDaiki Yamashige
National Cancer Center Hospital Department of Hepatobiliary and Pancreatic Oncology
Outcome results
None listed